Clofarabine 5′-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 24, 2011, Pages 9815-9820

  Aye, Yimon ^a   Stubbe, JoAnne ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Allosteric regulation; Oligomerization; Slow binding inhibitor

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CLOFARABINE; CYTIDINE DIPHOSPHATE; DEOXYRIBONUCLEOTIDE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; NUCLEOTIDE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; URIDINE DIPHOSPHATE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE; POLYPHOSPHATE; PROTEIN SUBUNIT; PYROPHOSPHATE; TRIPHOSPHORIC ACID;

ALLOSTERISM; ALPHA CHAIN; ARTICLE; BETA CHAIN; DRUG BINDING SITE; DRUG CYTOTOXICITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME STRUCTURE; ENZYME SUBUNIT; GEL PERMEATION CHROMATOGRAPHY; LEUKEMIA; PRIORITY JOURNAL; ALGORITHM; BINDING SITE; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; KINETICS; METABOLISM; MUTATION; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; TIME;

ADENINE NUCLEOTIDES; ADENOSINE TRIPHOSPHATE; ALGORITHMS; ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BINDING SITES; BIOCATALYSIS; CATALYTIC DOMAIN; DIPHOSPHATES; GUANOSINE TRIPHOSPHATE; HUMANS; KINETICS; MOLECULAR STRUCTURE; MUTATION; POLYPHOSPHATES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN SUBUNITS; RIBONUCLEOTIDE REDUCTASES; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 79959966626     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013274108     Document Type: Article

References (32)

1. Bonate PL, et al. (2006) Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat Rev Drug Discovery 5:855-863. (Pubitemid 44480539)
2. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F (2009) Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 78:1351-1359.
3. Gandhi V, Plunkett W (2006) Clofarabine: Mechanisms of action, pharmacology and clinical investigations. Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy, ed GJ Peters (Humana Press, Totowa, NJ), pp 153-171.
4. Wang J, Lohman GJS, Stubbe J (2007) Enhanced subunit interactions with gemcitabine- 5′-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci USA 104:14324-14329 and references cited therein.
5. Carson DA, et al. (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 89:2970-2974.
6. Lofti K, et al. (1999) Biochemical pharmacology and resistance to 2-chloro-2′-arabinofluoro- 2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 5:2438-2444.
7. Parker WB, et al. (1991) Effects of 2-chloro-9-(2′-deoxy-2′- fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51:2386-2394.
8. Xie KC, Plunkett W (1995) Metabolism and actions of 2-chloro-9-(2′- deoxy-2′-fluoro- D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res 55:2847-2852.
9. Xie KC, Plunkett W (1996) Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoidcells with 2-chloro-(2′-deoxy-fluoro-D- arabinofuranosyl) adenine. Cancer Res 56:3030-3037.
10. Wang J, Lohman GJS, Stubbe J (2009) Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5′-diphosphate. Biochemistry 48:11612-11621.
11. Lohman GJS, Stubbe J (2010) Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2′,2′-difluoro-2′-deoxycytidine 5′-triphosphate: Covalent modification. Biochemistry 49:1404-1417.
12. Harris G, Ashley GW, Robins MJ, Tolman RL, Stubbe J (1987) 2′-Deoxy-2′-halonucleotides as alternate substrates and mechanism-based inactivators of Lactobacillus leichmannii ribonucleotide reductase. Biochemistry 26:1895-1902. (Pubitemid 17067866)
13. Stubbe J, van der Donk WA (1998) Protein radicals in enzyme catalysis. Chem Rev 98:705-762. (Pubitemid 128631440)
14. Licht SS, Stubbe J (1999) Mechanistic inverstigations of ribonucleotide reductases. Comprehensive Natural Product Chemistry, ed CD Poulter (Elsevier, Amsterdam), pp 163-204.
15. Nordlund N, Reichard P (2006) Ribonucleotide reductases. Annu Rev Biochem 75:681-706.
16. Kashlan OB, Cooperman BS (2003) Comprehensive model for allosteric regulation of mammalian ribonucleotide reductase: Refinements and consequences. Biochemistry 42:1696-1706. (Pubitemid 36205978)
17. Rofougaran R, Vodnala M, Hofer A (2006) Enzymatically active mammalian ribonucleotide reductase exists primarily as an α6β2 octamer. J Biol Chem 281:27705-27711. (Pubitemid 44414484)
18. Ingemarson R, Thelander L (1996) A kinetic study on the influence of nucleoside triphosphate effectors on subunit interaction in mouse ribonucleotide reductase. Biochemistry 35:8603-8609. (Pubitemid 26240195)
19. Fairman JW, et al. (2011) Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol 18:316-322.
20. Thelander L (2007) Ribonucleotide reductase and mitochondrial DNA synthesis. Nat Genet 39:703-704 and references cited therein.
21. Stubbe J, Nocera DG, Yee CS, Chang MCY (2003) Radical initiation in the class I ribonucleotide reductase: Long-range proton-coupled electron transfer. Chem Rev 103:2167-2202.
22. Reichard P, Eliasson R, Ingemarson R, Thelander L (2000) Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase. J Biol Chem 275:33021-33026.
23. Morrison JF, Walsh CT (1988) The behaviour and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301.
24. Copeland RA (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (Wiley-Interscience, New York).
25. Copeland RA (2000) Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis (Wiley, New York), 2nd Ed.
26. Cook PF, Cleland WW (2007) Enzyme Kinetics and Mechanism (Garland Science, London), pp 195-204.
27. Cory JG, et al. (1985) Nucleoside 5′-diphosphates as effectors of mammalian ribonucleotide reductase. J Biol Chem 260:12001-12007. (Pubitemid 16228356)
28. Chimploy K, Mathews CK (2001) Mouse ribonucleotide reductase control: Influence of substrate binding upon interactions with allosteric effectors. J Biol Chem 276:7093-7100.
29. Nakamura CE, Abeles RH (1985) Mode of interaction of β-hydroxy- β-methylglutaryl coenzyme A reductase with strong binding inhibitors: Compactin and related compounds. Biochemistry 24:1364-1376.
30. Hassan AQ, Wang Y, Stubbe J (2008) Methodology to probe subunit interactions in ribonucleotide reductases. Biochemistry 47:13046-13055.
31. Steeper JR, Steuart CC (1970) A rapid assay for CDP reductase activity in mammalian cell extracts. Anal Biochem 34:123-130.
32. Cory JG, Russell SA, Mansell MM (1973) A convenient assay for ADP reductase activity using Dowex-1-borate columns. Anal Biochem 55:449-456.